NORMIVA

Allergan Sales, LLC

Application Filed: 2016-09-16
Trademark Application Details
Trademark Logo NORMIVA
734
Live/Pending
FIFTH EXTENSION - GRANTED
Research OneLook Acronym Finder
Serial Number87174411
Mark Drawing Code4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Law Office AssignedM10
Employee NameELLINGER FATHY, JESSIC

Timeline

2016-09-16Application Filed
2017-01-31Published for Opposition
2019-09-24Location: INTENT TO USE SECTION
2019-09-24Status: Live/Pending
2019-09-25Transaction Date

Trademark Applicants & Owners

Owner: Allergan Sales, LLC
AddressI 5 Giralda Farms Madison DE 07940
Legal Entity TypeLimited Liability Company
Legal Entity StateDE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

SUSAN J. HINCHEY
ALLERGAN, INC.
2525 DUPONT DRIVE
IRVINE, CA 92612

Good, Services, and Codes

International Codes:5
U.S. Codes:006,018,044,046,051,052
Type CodeType
GS0051Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Trademark Filing History

DescriptionDateEvent Coding
NEW APPLICATION ENTERED IN TRAM2016-09-201 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM2016-09-212 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER2016-12-213 DOCK D:Assigned to Examiner
APPROVED FOR PUB - PRINCIPAL REGISTER2016-12-224 CNSA P:
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED2017-01-115 NONP E:E-Mail
PUBLISHED FOR OPPOSITION2017-01-316 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED2017-01-317 NPUB E:E-Mail
NOA E-MAILED - SOU REQUIRED FROM APPLICANT2017-03-288 NOAM E:E-Mail
TEAS EXTENSION RECEIVED2017-08-169 EEXT I:Incoming Correspondence
EXTENSION 1 FILED2017-08-1610 EXT1 S:
EXTENSION 1 GRANTED2017-08-1611 EX1G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2017-08-1812 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2018-01-3013 EEXT I:Incoming Correspondence
EXTENSION 2 FILED2018-01-3014 EXT2 S:
EXTENSION 2 GRANTED2018-01-3015 EX2G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2018-02-0116 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2018-09-0717 EEXT I:Incoming Correspondence
EXTENSION 3 FILED2018-09-0718 EXT3 S:
EXTENSION 3 GRANTED2018-09-0719 EX3G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2018-09-1120 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2019-03-0121 EEXT I:Incoming Correspondence
EXTENSION 4 FILED2019-03-0122 EXT4 S:
EXTENSION 4 GRANTED2019-03-0123 EX4G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2019-03-0524 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2019-09-2025 EEXT I:Incoming Correspondence
CASE ASSIGNED TO INTENT TO USE PARALEGAL2019-09-2426 AITU A:Allowance for Publication
EXTENSION 5 FILED2019-09-2027 EXT5 S:
EXTENSION 5 GRANTED2019-09-2428 EX5G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2019-09-2529 EXRA E:E-Mail
ABANDONMENT - NO USE STATEMENT FILED2020-06-0330 ABN6 S:
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED2020-06-0331 MAB6 E:E-Mail

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed